APRE Bathi saben saham sajrone rolas wulan pungkasan Aprea

Demand for targeted oncology therapy remains colossal due to the complexity of genetic mutations. Aprea Therapeutics (APRE) is developing an ecosystem of drugs to combat DNA damage, creating closed treatment protocols. The rolling net income per share trend demonstrates that the parameter value reaches -0.70. Supply stability is ensured here by strict climate control during the transportation of medications.

APRE (Aprea Therapeutics) riwayat Bathi resik saben saham sajrone 12 wulan pungkasan saka 04.07.2022 nganti 14.11.2026

Aprea Therapeutics Inc. - rincian analitis lan metrik utama (APRE)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Aprea|APRE - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar Aprea Therapeutics, Inc.|APRE - Nilai Bisnis

- data nilai buku modal saham:

Nilai Buku saben Saham Aprea Therapeutics|APRE - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku aprea.com|APRE - Aset Perusahaan

- indikator beban utang lan likuiditas:

Utang marang Ekuitas Aprea Therapeutics|APRE - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Aprea|APRE - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Aprea Therapeutics, Inc.|APRE - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Aprea Therapeutics|Indikator likuiditas cepet aprea.com

- indikator pendapatan resik lan kelipatan nilai:

APRE - Bathi pungkasan|Bathi mangsa ngarep Aprea Therapeutics|APRE - Rasio rega pasar marang bathi resik|Pangali Forward P/E Aprea|APRE - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Aprea Therapeutics, Inc.|APRE - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Aprea Therapeutics|APRE - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan aprea.com|APRE - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Aprea Therapeutics

- rincian pendapatan lan dodolan:

APRE - Pendapatan tahunan perusahaan|Volume dodolan mangsa ngarep perusahaan Aprea|APRE - Rega marang dodolan|Multiplikator Forward P/S Aprea Therapeutics, Inc.

Analisis dhasar perusahaan:aprea.com (APRE)

Operational business resilience is determined by the ability to generate real income per unit of shareholder equity. This metric aggregates annual net income, excluding the impact of total issuance to assess actual profitability. For Aprea Therapeutics (APRE), which is protected by the humanitarian status of oncology research in the US, this indicator reflects the efficiency of R&D expenditures. By analyzing the change in EPS over 12 months, an investor assesses the risk of capital freeze amid market stagnation.

Analisis perusahaan pesaing